Does Caralluma fimbriata extract (Slimaluma) reduce the risk factors of metabolic syndrome in overweight and obese adults?
The effects of Caralluma fimbriata extract (Slimaluma) in combination with lifestyle intervention on the risk factors of metabolic syndrome in overweight and obese adults: a randomised controlled trial
Victoria University
50 participants
May 1, 2010
Interventional
Conditions
Summary
A 3-month intervention using encapsulated Caralluma fimbriata extract in combination with lifestyle intervention to investigate whether or not Caralluma fimbriata extract suppresses the appetite and decreases the risk factors of metabolic syndrome
Eligibility
Inclusion Criteria1
- Males and females aged 30-60 years with a body mass index (BMI) greater than 25 or a waist circumference > 94cm for males and >80cm for females.
Exclusion Criteria1
- Liver, kidney and heart disease, pregnancy, type 1 and type 2 diabetes with insulin medication, cigarette smoking and the use of any medication for weight loss.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Caralluma fimbriata extract capsule 500mg oral administration, twice per day before meals for three months. Water soluble, Caralluma fimbriata extract containing 27.8% Pregnane Glycosides and 13.3% Saponin Glvcosides. Lifestyle intervention focuses on healthy dietary intake based on the Dietary guidelines for Australian adults for three months.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000289011